Researchers at the University of Michigan reviewed published and unpublished trials of serotonin receptor inhibitors (SRI) for the treatment of autism spectrum disorders (ASD). The published literature showed a significant benefit of SRIs for ASD behaviors, but the researchers found significant evidence of publication bias in all analyses. When analyses were corrected for publication bias, the researchers found no significant benefit of SRIs for the treatment of ASD. Results will be published in Pediatrics.
Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.
Mad in America has made some changes to the commenting process. You no longer need to login or create an account on our site to comment. The only information needed is your name, email and comment text. Comments made with an account prior to this change will remain visible on the site.